Granules India Limited Q1 FY27 Earnings Call Summary

Revenue

Margin

Demand

Guidance

Tone

Event Participants

Executives

5
Krishna Prasad Chigurupati, Priyanka Chigurupati, Sanjay Kumar, P.V. Srinivas, Mukesh Surana

Analysts

11
Sameer Baisiwala, Yashika Gogia, Vignesh Iyer, Krisha Kansara, Sajal Kapoor, Shashank Krishnakumar, Tushar Manudhane, Nishita Shanklesha, Ritwik Sheth, Rashmi Shetty, Suhani Singh

Financials & KPIs

Metric	Reported	Commentary
Revenue	₹1,476.8 crores	Up 22% YoY, broadly flat QoQ; led by finished dosages, complex generics, North America and Europe.
Gross Margin	65.6%	+74 bps YoY; supported by complex generic mix; Q1 insulated from RM inflation by U.S. opening inventory.
EBITDA	₹338.9 crores	+37% YoY; margin 22.9% (+256 bps YoY, -99 bps QoQ).
PBT (pre-exceptional)	₹240.4 crores	+41% YoY, supported by gross margin expansion.
PAT	₹180 crores	+60% YoY; strongest Q1 ever per management.
R&D Expenses	₹88 crores (6% of sales)	+30% YoY; up from 5.3% of sales in Q4 FY26; focused on CNS, oncology, MUPS and complex formulations.
Operating Cash Flow	₹387.4 crores	vs ₹100.3 crores in Q4 FY26; aided by lower receivables, higher U.S. sales and stable working capital.
Net Debt	₹101.2 crores	vs ₹402.1 crores at FY26 close; Net Debt/EBITDA at 0.07x.
ROCE	18%	vs 17.6% in Q4 FY26; improving on steady trajectory.
Capex	₹89 crores in Q1	FY27 guidance unchanged at ₹600 crores; Genome Valley major investment completed.
Working Capital / Sales	29%	vs 30% in Q1 FY26 and Q4 FY26; inventory build supports growth while receivables managed well.
Complex Generics % of Finished Dosages	50%	vs 39% a year ago; reflects mix shift toward differentiated products.
Peptide CDMO Revenue	CHF5 million	+100% YoY; in line with expectations, moderated sequentially after strong Q4.

Geographic & Segment Commentary

Complex Generics / Finished Dosages: Complex generics rose to 50% of finished dosages vs 39% YoY. Growth was led by finished dosages and supported by North America and Europe, making the revenue base more diversified. 9 launches are expected in FY27 pending FDA clearance of Gagillapur.
Peptide CDMO: Q1 revenue of CHF5 million grew >100% YoY; 3 new customer projects initiated (1 pharma, 2 cosmetics) and 2 discontinued products re-engaged. Zurich and Hyderabad now operate as an integrated R&D organization; TAG-assisted peptide synthesis work has commenced. FY27 focus is delivering annual PAT-positive performance with H2 expected stronger.
Oncology: Contribution is currently minimal; Vizag has been used for CMO and API sales. First self-developed, fully backward-integrated oncology product launches in FY28-29 with global expansion. 9-13 products are in various development phases; 2 U.S. ANDAs, 2 EU dossiers and ~14 country extensions filed.
North America / Controlled Substances: GPI is now the 27th largest U.S. generic company vs 74th five years ago, and the 4th largest in controlled substances. GPI utilization is ~70% with expansion needed by end-2028; quota is sufficient to reach target market shares. 1-2 new controlled launches expected in the next 1.5-2 years, plus ~5 IP-based products.
Europe & ROW: Strong YoY growth ex-Senn, driven by both API and finished dosages from past European filings. Sequential softness was caused by cost pressures on legacy 5, intentional supply holds on pricing, and pending approvals—not an underlying demand trend.

Company-Specific & Strategic Commentary

Gagillapur Remediation: Remediation is essentially complete; FDA meeting held in January and no concerns raised on adequacy or pace. 7 of 8 facilities now carry clean EIRs; 330+ customer/regulatory audits over 2 years without a single critical observation. 9 applications are ready to launch once clearance is received.
Complex Generics & First-to-File: 2 sole first-to-file products are in the public domain with litigation expected; sodium oxybate is cited as a capability-driven sole FTF filing. R&D investments are concentrated on high-barrier areas—CNS, oncology, MUPS and complex formulations.
Peptide Platform Expansion: Senn's peptide CDMO is being scaled across Swiss and India operations; Zurich infrastructure upgrades (solid-phase reactors, purification columns, lyophilization) are underway and land has been earmarked for a peptide facility at Vizag. Medium-term goal is 5x revenue over 5 years, with a $50 million revenue run-rate at 30%+ EBITDA as an intermediate proof point.
Genome Valley: Facility adds ~40% to formulation capacity; utilization expected to cross 50% by year-end. Capex is shifting from major builds to digitalization and modular growth projects.
Balance Sheet & Capital Allocation: Net debt/EBITDA is 0.07x, with ₹387.4 crores Q1 operating cash flow. Dividend payout policy is under review for a potential increase, per management.

Guidance & Outlook

Metric	Guidance / Outlook	Commentary
Revenue Growth FY27	Continue strong growth trajectory	No quantitative guidance given; management expressed confidence in sustained growth.
EBITDA Margin	22-23% expected to continue	Supported by complex generic mix; RM inflation offset partly by mix and pricing actions.
Capex	₹600 crores for FY27	₹89 crores spent in Q1; spend to pick up on digitalization and modular growth projects.
R&D Expense	5.5-6% of sales	Majority of spend directed toward complex generics.
Genome Valley Utilization	>50% by FY27 year-end	Ramp-up progressing; new filings/product transfers supporting utilization.
U.S. Launches	~9 launches in FY27	Pending FDA clearance of Gagillapur; plus IP-linked approvals as they mature.
Peptide CDMO	PAT positive for FY27; H2 stronger than H1; annual revenue at least Q1 run-rate annualized	Project-driven variability expected; medium-term milestone of $50M revenue at 30%+ EBITDA by mid-5-year journey.
Oncology Ramp-up	First product launch in FY28-29	9-13 products in development; global geographic expansion planned.

Risks & Constraints

Risk	Context
FDA clearance timing at Gagillapur	Remediation is complete and no concerns raised to date, but FDA visit timing is unknown. 9 ready-to-launch applications remain blocked until clearance; delay would push back the U.S. launch pipeline.
Raw material / input cost inflation	West Asia geopolitical tensions are driving inflation in select raw materials, packing inputs, freight and supply chain costs. Q1 was insulated by U.S. opening inventory; sustained pressure could impact margins, partially mitigated via pricing actions and cost pass-throughs.
Peptide CDMO revenue lumpiness	Project-driven business posted negative EBITDA in Q1 after a positive Q4; long lead times and project mix cause quarterly swings. FY27 PAT-positive target depends on second-half project timing and execution.
Litigation / IP risk on complex launches	First-to-file and controlled substance products (e.g., Dyanavel, Adzenys) are subject to ongoing litigation; management will not disclose timing. Outcomes could affect launch schedules.
Working capital expansion	Growth in the U.S. and non-U.S. markets may increase receivable days; management expects to stay within a range but working capital-to-sales could rise above the current 29%.

Q&A Highlights

Growth Trajectory and Margin Sustainability

Question: Can the 22% YoY growth and 22-23% EBITDA margin continue? (Nishita Shanklesha)
Answer: Management is confident growth will continue and EBITDA margins will remain in the 22-23% range (K. P. Chigurupati).
Question: Will favorable mix offset RM pressures in the next 1-2 quarters? (Shashank Krishnakumar)
Answer: RM pressures are high, but the complex generic mix is helping and is expected to continue (K. P. Chigurupati).

Gagillapur Remediation and U.S. Launch Pipeline

Question: Did production stop at Gagillapur? Are GLS product extensions risk mitigation? (Tushar Manudhane)
Answer: Production never stopped except an intentional 2-day pause; only new approvals are blocked. GLS transfers are both risk mitigation and new filings to keep sites regulatory ready (Priyanka Chigurupati).
Question: What is the pending approval count? (Tushar Manudhane)
Answer: 9 approvals pending facility clearance (~$11B market), 9 IP-linked products, and 5 more in the U.S.; total 23-24 filings pending approval (Priyanka Chigurupati).

Genome Valley Ramp-up and Filings

Question: How is GLS utilization ramping and are new filings coming from this facility? (Shashank Krishnakumar)
Answer: Utilization should cross 50-60% by year-end; if full capacity were used today, another plant would already need to be built. Most new filings are still from GGP, while GLS has product extensions and some new filings for risk mitigation (K. P. Chigurupati, Priyanka Chigurupati).

Peptide CDMO – Milestones and FY27 Outlook

Question: What milestone would prove the peptide platform is structurally self-sustaining? (Sajal Kapoor)
Answer: A $50 million revenue run-rate with 30%+ EBITDA margin, around the middle of the 5-year journey, plus 3 customer wins of $10M+ annual potential (Sanjay Kumar).
Question: How should FY27 peptide revenues be modeled? (Rashmi Shetty)
Answer: Annual revenue should be at least the Q1 run-rate annualized, with H2 stronger; the goal is PAT-positive for the year (Sanjay Kumar).

Peptide CDMO – Capex and EBITDA Volatility

Question: What is the India peptide capex and why was Q1 EBITDA negative? (Krisha Kansara)
Answer: Initial estimates are ~₹100 crores for the intermediate side and ~₹200 crores for the API side. Q1 EBITDA loss is due to project/product mix, opex timing and long cycle times—not a one-off (Sanjay Kumar).
Question: What was the remediation expense in Q1? (Krisha Kansara)
Answer: Not significant; less than $1 million per quarter for the last couple of quarters (Mukesh Surana).

Oncology Pipeline and Filings

Question: Where does the oncology business stand? (Rashmi Shetty)
Answer: Vizag is currently CMO; first self-developed, fully backward-integrated product launches in FY28-29 with global expansion. 2 U.S. ANDAs, 2 EU dossiers and ~14 extensions filed; 9-13 products in development (Priyanka Chigurupati).
Question: How many oncology filings are targeted this fiscal? (Sameer Baisiwala)
Answer: No specific guidance; run-rate is improving (Priyanka Chigurupati).

Controlled Substances and GPI Capacity

Question: What is the controlled substance launch pipeline for FY27/FY28? (Ritwik Sheth)
Answer: No new launches in FY27; 1-2 launches expected in the next 1.5-2 years, plus ~5 IP-based products. Growth will come from existing molecules gaining share (Priyanka Chigurupati).
Question: What is GPI's utilization and growth potential? (Sameer Baisiwala)
Answer: ~70% utilization, with significant leeway given the low-volume, high-value product mix; expansion will be needed by end-2028 (K. P. Chigurupati, Priyanka Chigurupati).

Working Capital, Cash Flow and Dividend

Question: What drove the large jump in operating cash flow? (Tushar Manudhane)
Answer: No incremental working capital investment, substantially reduced receivables from higher U.S. sales, and modest capex (Mukesh Surana).
Question: Should working capital be modeled at 29% or 33%? (Vignesh Iyer)
Answer: We remain within a range; receivable days could rise with growth but will be managed tightly (Mukesh Surana).
Question: Is the dividend payout policy being revisited? (Ritwik Sheth)
Answer: The policy has been conservative; internal discussions are underway to potentially increase it (Mukesh Surana).

Europe Sequential Softness

Question: Is Europe's QoQ softness demand-related or timing? (Suhani Singh)
Answer: Not a demand trend; cost pressures on legacy 5 led to intentional supply holds on pricing, combined with pending approvals. New areas such as controlled substances will drive sequential growth (Priyanka Chigurupati).

Key Takeaway

Granules India delivered its strongest Q1 ever, with revenue up 22% YoY to ₹1,476.8 crores, EBITDA up 37% to ₹338.9 crores (22.9% margin), and PAT up 60% to ₹180 crores. ROCE improved to 18%, net debt/EBITDA fell to 0.07x, and operating cash flow reached ₹387.4 crores. Complex generics rose to 50% of finished dosages (from 39%), and the peptide CDMO grew over 100% YoY to CHF5 million. Management reaffirmed confidence in sustained growth, guided for FY27 EBITDA margins of 22-23%, capex of ₹600 crores, R&D at 5.5-6% of sales, ~9 U.S. launches pending FDA clearance, and peptide PAT-positive status for FY27 with a stronger H2. Key watch points include Gagillapur clearance timing, West Asia-driven cost inflation on gross margins, and peptide project lumpiness. Strategy centers on complex generics and first-to-file opportunities, controlled substances, oncology ramp-up from FY28-29, and scaling the peptide platform toward a $50 million revenue milestone.